ArticleScientific reports2023

Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases.

Limin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.